Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia

NEXT STORY
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
PREV STORY
Global Portable Medical Devices Market (2020 to 2025) – by Product, Application, End-user and Geography
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study

First patient enrolled in Phase 3 hip OA registration trial in late December 2018; ...

author_avatar
NASDAQ Market News

Radius Health, Inc.: Second Quarter and Year-to-Date Results

author_avatar
NASDAQ Market News

Eldorado Gold Acquires Shares of Probe Metals Inc.

author_avatar
NASDAQ Market News